Just days after sources said the European Commission was preparing to issues fines against generic drug makers for anticompetitive practices, reports say authorities in the US are also revamping their efforts against unfair tactics in the pharmaceutical industry.
According to reports, the Federal Trade Commission launched new investigations into pay-for-delay agreements made between drug manufacturers, in the wake of a Supreme Court decision last year that armed antitrust law with the legal ability to fight such pacts.
Pay-for-delay deals allow a brand name drug maker to pay its cheaper, generic rival to keep its competition off the shelf.
With the Supreme Court ruling, the FTC has launched probes into agreements made between generic and brand name companies; according to filings, the regulator is eyeing Forest Laboratories and Endo International.
Reports say the investigations could lead to fines and lawsuits.
Full content: Businessweek
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI